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Background:  Heart failure (HF) is associated with an increased risk of thrombotic events, which can be reduced by adequate drug treatment. We 
assessed the temporal relationship of the incidence of myocardial infarction (MI) and stroke, and the specific cardiovascular treatment that was 
given.
Methods:  Data were obtained from the PHARMO Record Linkage System, a population-based registry of pharmacy records linked with hospital 
discharge records in The Netherlands. Patients were selected based on a first hospital discharge diagnosis of documented HF. Two time intervals 
were compared: 1998-2002 and 2003-2007. We analyzed prescribed medication in the first 90 days after hospitalization, and the occurrence of MI 
and strokes in the first year after hospitalization. Logistic-regression analysis was performed to calculate odds ratios (OR) between the two periods.
Results:  We identified 6526 patients in 1998-2002 and 6369 patients from 2003-2007. During the first year after acute HF, the incidence of 
thrombotic events was 4.1% and 3.4% in the two periods, respectively. After adjustment for age and previous thrombotic events the incidence was 
21% lower in 2003-2007 (Table). Prescription of ACE-inhibitors and beta-blockers has increased in the recent years, but were still prescribed to only 
60% of HF patients (Table).
Conclusion:  The incidence of thrombotic events appears to have decreased in patients with acute HF, which may be due to better use of 
medication. However, many patients remain undertreated.
Differences between the time-periods 1998-2002 and 2003-2007 in thrombotic events and medication
1998-2002
(n=6526)
2003-2007
(n=6369)
OR (95%CI)
Overall atherothrombotic events 265 (4.1) 214 (3.4) 0.79 (0.66 -0.95)†
Myocardial infarction 204 (3.1) 160 (2.5) 0.76 (0.62 -0.94)†
Ischemic stroke 63 (1.0) 55 (0.9) 0.88 (0.61 -1.26)†
ACE inhibitor or ARB 3760 (58) 4010 (63) 1.25 (1.17-1.34)
Beta-blockers 2552 (39) 3806 (60) 2.31 (2.16-2.48)
Coumarins 2051 (31) 2328 (37) 1.26 (1.17-1.35)
Antiplatelets 1962 (30) 2196 (34) 1.22 (1.14-1.32)
Statins 1165 (18) 2065 (32) 2.21 (2.03-2.40)
Footnote: ARB=Angiotensin Receptor Blocker. OR=Odds Ratio. †Adjusted for age and previous cardiovascular events.
